This is a preview of subscription content, access via your institution
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Original article
Lheureux, S. et al. Adavosertib plus gemcitabine for platinum-resistant or platinum-refractory recurrent ovarian cancer: a double-blind, randomised, placebo-controlled, phase 2 trial. Lancet 397, 281–292 (2021)
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Killock, D. WEE1 inhibition after platinum resistance. Nat Rev Clin Oncol 18, 194 (2021). https://doi.org/10.1038/s41571-021-00482-4
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41571-021-00482-4
This article is cited by
-
A targetable MYBL2-ATAD2 axis governs cell proliferation in ovarian cancer
Cancer Gene Therapy (2023)